Top Markets
Coin of the day
Brickell Biotech, Inc. Brickell Biotech, Inc.

Brickell Biotech, Inc.

BBI
Rankning i aktier #40377
Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical... Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical development phase, dedicated to creating prescription medicines for various debilitating conditions, including autoimmune and inflammatory disorders, primarily within the United States. Its product pipeline includes sofpironium bromide, which has successfully finished Phase III clinical trials for treating excessive underarm sweating (primary axillary hyperhidrosis). Other notable candidates are BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent stimulator of interferon genes (STING) inhibitor, being explored for autoinflammatory and rare genetic illnesses. The company is also advancing next-generation kinase inhibitors. Brickell Biotech collaborates with several partners, such as Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. Established in 2009, its main office is located in Boulder, Colorado.
Aktiekurs
$2.35
Senast synkroniserad: 2022-09-07
Marknadsvärde
$162.94K
Förändring (1 dag)
2.17%
Förändring (1 år)
0.00%
Land
US
Handel Brickell Biotech, Inc. (BBI)

Kategori

EPS för Brickell Biotech, Inc. (BBI)
EPS per 2026 TTM: 0
Enligt Brickell Biotech, Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för Brickell Biotech, Inc. från 2026 till 2026
EPS vid slutet av varje år
År EPS Ändra
Inte tillräckligt med data för de angivna datumen.
EPS för liknande företag eller konkurrenter